Skip to main content

ImmunityBio

ImmunityBio Inc is an American clinical and commercial-stage immunotherapy enterprise specializing in the research, development, manufacturing, and commercialization of innovative biological therapeutic product candidates (including lymphokine-activated killer cells, monoclonal antibodies, fusion proteins, and cancer vaccines) designed to activate the patient's adaptive and innate immune system to combat complex cancers and infectious diseases. The company operates advanced biotechnology manufacturing and research complexes, prominently featuring FDA-approved immunotherapy products. Its core business operations encompass immunotherapy drug development, biological manufacturing, clinical trial administration, and commercial pharmaceutical distribution. Revenue is derived primarily from commercial product sales of approved immunotherapies and strategic biopharmaceutical collaboration agreements. ImmunityBio holds a leading market position in immunotherapy innovation and cancer vaccine development. The company is headquartered in Culver City, California, United States, and its common stock trades on the Nasdaq Global Select Market under the ticker IBRX.

6 of the funds FundTelligence covers report a position in ImmunityBio.

Legal name
ImmunityBio Inc
Sector
Health Care
Country
United States
Funds holding it
6

Funds holding ImmunityBio

Loading...